*Patient with ankylosing spondylitis and
scleroderma renal crisis*

**Aliki I. Venetsanopoulou, Ourania Argyropoulou,
Athanasios G. Tzioufas**

Mediterr J Rheumatol 2018;29(2):86-8

E-ISSN: 2529-198X

Patient with ankylosing spondylitis and scleroderma renal crisis

Aliki I. Venetsanopoulou, Ourania Argyropoulou, Athanasios G. Tzioufas

Department of Pathophysiology, Medical School, University of Athens, Athens, Greece

ABSTRACT

We report a 56-year-old man with a history of ankylosing spondylitis and systemic scleroderma. The patient had been diagnosed with ankylosing spondylitis 20 years ago and had been receiving treatment with NSAIDs and anti TNF α drugs. He referred to our rheumatology department for Raynaud's phenomenon, arthralgias and weight loss. Physical examination revealed stiffness of the skin with difficulty in pinching (mainly at lower extremities, from knee to ankle). Soon after his first visit to our department, he developed renal scleroderma crisis with abrupt increase in blood pressure, decline in renal function, and microangiopathic haemolytic anaemia in accordance with positive antinuclear autoantibodies and positive anti-topoisomerase I antibody (anti-Scl70). This is one of the few reports in the literature of coexistence of ankylosing spondylitis and systemic scleroderma. A genetic correlation seems to be an explanation in some patients who carry one or two susceptibility alleles to both diseases. Thus, this might be the case of a 'genetic trap' in which distinct genes are cooperating to favour the susceptibility to two different HLA-associated systemic autoimmune diseases.

Mediterr J Rheumatol 2018;29(2):86-8

<https://doi.org/10.31138/mjr.29.2.86>

Submitted 01/12/2017, Revised Form 19/03/2018, Accepted 04/04/2018

Keywords: Ankylosing spondylitis, Systemic Scleroderma

A 56-year-old man with a known history of ankylosing spondylitis (AS) was referred to our rheumatology department for Raynaud's phenomenon, arthralgias and body weight loss (~ 10% BMI). The patient had been receiving treatment for 10 years with an anti-TNF α agent. Six months before, due to his new symptoms, 200mg of hydroxychloroquine and 10mg of prednisolone per day were added. However, the patient showed no improvement and visited the external rheumatology department of the Clinic of Pathological Physiology of the Laikon General Hospital for a second opinion.

Corresponding author:

Aliki I. Venetsanopoulou
Rheumatologist
Department of Pathophysiology
Faculty of Medicine, National and
Kapodistrian University of Athens
75 M. Asias str., 11527, Athens, Greece
E-mail: alikivenetsanopoulou@yahoo.com
Tel. no.: +30 210 7462513,
Fax no.: +30 210 7462664

According to his medical history, he had ankylosing spondylitis that started with inflammatory back pain 20 years ago, with radiographic findings of sacroiliitis and spinal involvement (**Figures 1a, 1b**) and a positive HLA-B27 test. He had been receiving treatment with NSAIDs and anti TNF α drugs (adalimumab that was switched 6 months before to etanercept). He also suffered from depression and he had been treated with citalopram and alprazolam. He was a smoker (30 years, 1 pack a day), a social drinker and he had free family history.

On physical examination, Raynaud's phenomenon was observed in both hands, with joint pain in all limbs and stiffness of the skin with difficulty in pinching (mainly at lower extremities, from knee to ankle). The rest of the physical examination and vital signs were normal. Laboratory tests were without pathological findings, with only an increase of ESR (57mmHg). Due to the signifi-

Figure 1a. Sacroiliac joint radiography demonstrating bilateral sacroiliitis

Figure 1b. Lumbar spine X-ray with marginal syndesmophytes

cant weight loss and his smoking, a chest and upper/lower abdominal CT scan was requested. The results were without abnormal findings. Further evaluation for Raynaud's phenomenon and stiffness of the skin included serum protein electrophoresis, hepatitis control and immunological tests (antinuclear autoantibodies [ANA], antibodies to Extractable Nuclear Antigens [ENA], rheumatoid factor, anti-topoisomerase I antibody [anti-Scl70] and cryoglobulins [CRYO]). While waiting for the results, hydroxychloroquine was discontinued, prednisolone was reduced to 7.5 mg per day and, as he suffered from arthralgias, 15mg of methotrexate and 5mg of folate per week were added.

After one month, on his scheduled appointment the patient presented with an exacerbation of his symptoms. In particular, he had arthralgias, dyspnoea and orthopnoea. Physical examination revealed an extension of skin hardening (trunk, upper and lower extremities) (**Figure 2a, 2b**), unexplained velcro-like inspiratory movements and increased blood pressure (200/100 mmHg). Laboratory tests were performed immediately, and rapid decline of renal function was revealed (Creat: 6.78 mg / dl, Urea: 75mg / dl), with microangiopathic haemolytic anaemia (Ht 29.3%, Hb 8.1 gr/dl, MCV 91) and increased inflammation markers (CRP 100 mg/dl, TKE 47 mmHg). The immunological tests were positive for ANA (1/1280 fsp),

Figure 2a, 2b. Stiffness of patient skin with difficulty in pinching

Anti-SSA/ Ro and Anti-Scl-70. As he had rapidly deteriorating renal function, the patient was admitted to the clinic for further investigation and management.

Based on his clinical picture and the abrupt increase in blood pressure, decline in renal function, microangiopathic haemolytic anaemia and, in accordance with the positive immunological tests, a diagnosis of scleroderma renal crisis was made. The patient was treated with an angiotensin converting enzyme inhibitor (captopril) in order to obtain a gradual adjustment of blood pressure. At the same time, he began haemodialysis sessions. However, he presented thrombocytopenia and leukopenia due to captopril and his treatment switched to an angiotensin II receptor blocker (valsartan). His blood pressure was successfully reduced to normal levels, but his creatinine remained high and he continued on haemodialysis. Currently, 1 year after his initial admission to the hospital, the patient remains on chronic haemodialysis and is treated for AS with a new biologic agent (secukinumab, a human interleukin-17A antagonist) at a dose of 150mg per month with satisfactory results and a BASDAI improvement.

DISCUSSION

We report the case of a patient who had AS and developed diffuse systemic sclerosis (SSc). Someone could suggest that scleroderma occurrence may be associated with our patient's previous treatment. There are several factors have been identified as possible triggers of SSc. These include drugs (e.g., vitamin K, cocaine, penicillamine and some chemotherapeutic agents), and chemicals (e.g., silica, pesticides, aliphatic hydrocarbons). However, the exact role of TNF- α drugs remains controversial. In vitro studies have shown that TNF α inhibits the activity of fibroblasts, acts as a potent inducer of metalloproteinases and thus, inhibition of TNF- α could worsen fibrosis.^{1,2,3} On the other hand, inhibition of TNF- α seems to improve fibrosis in animal experimental models.⁴ Clinical studies have showed that, in some cases, anti-TNF α therapy worsened the fibrotic cellulitis and had infectious complications.⁵ Also, development of morphea, a localized scleroderma lesion, has been reported in patients treated with anti-TNF α drugs,^{6,7,8} suggesting a rare paradoxical side effect. However, in a small series of cases, anti-TNF α drugs are beneficial for the treatment of SSc by improving arthritis and reducing the modified Rodnan score for skin (mRSS).⁹ Eventually, could this be a case of AS coexistence with Systemic Scleroderma? It is well known that AS rarely coexists with other inflammatory joint diseases. Cases of AS have been reported in patients who had systemic lupus erythematosus,¹⁰ mixed connective tissue disease,¹¹ or Behçet's disease.¹² AS and SSc rarely occur in combination.^{13,14} This is one of the few reports in the literature of coexistence of the two diseases. A genetic correlation seems to be an explana-

tion. Particularly, there are reports of association of AS and SSc in the presence of HLA specificities known to be associated with these two diseases: HLA*B27, associated with susceptibility to AS; and HLA*B35, DRB1*11, DRB1*15, DRB3, DQB1*03, and DQB1*06, associated with SSc in different populations.¹⁵ Thus, this might be the case of a 'genetic trap' in which distinct genes are cooperating to favour the susceptibility to two different HLA-associated systemic autoimmune diseases. Hopefully, future research will identify the environmental factors that trigger the expression of both diseases in the same patient.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

REFERENCES

1. Distler JH, Schett G, Gay S, Distler O. The controversial role of tumor necrosis factor alpha in fibrotic diseases. *Arthritis Rheum.* 2008;58:2228-35. doi: 10.1002/art.23645.
2. Chua CC, Chua BH: Tumor necrosis factor-alpha induces mRNA for collagenase and TIMP in human skin fibroblasts. *Connect Tissue Res.* 1990;25:161-70.
3. Mauviel A, Daireaux M, Redini F, Galera P, Loyau G, Pujol JP: Tumor necrosis factor inhibits collagen and fibronectin synthesis in human dermal fibroblasts. *FEBS Lett.* 1988;236:47-52.
4. Liu JY, Brass DM, Hoyle GW, Brody AR: TNF-alpha receptor knockout mice are protected from the fibroproliferative effects of inhaled asbestos fibers. *Am J Pathol.* 1998;153:1839-47.
5. Phumethum V, Jamal S, Johnson SR. Biologic therapy for systemic sclerosis: a systematic review. *J Rheumatol.* 2011;38:289-96.
6. Stewart FA, Gavino AC, Elewski BE. New side effect of TNF-alpha inhibitors: morphea. *Skinmed.* 2013;11:59-60. PubMed PMID: 23540081.
7. Ramírez J, Hernández MV, Galve J, Cañete JD, Sanmartí R. Morphea associated with the use of adalimumab: a case report and review of the literature. *Mod Rheumatol.* 2012;22:602-4. doi: 10.1007/s10165-011-0550-4. Epub 2011 Nov18. Review. PubMed PMID: 22095405.
8. Mattozzi C, Richetta AG, Cantisani C, Giancristoforo S, D'Epiro S, Gonzalez Serva A, et al. Morphea, an unusual side effect of anti-TNF-alpha treatment. *Eur J Dermatol.* 2010;20:400-1. doi: 10.1684/ejd.2010.0946. Epub 2010 Mar 19. PubMed PMID: 20299314.
9. Bosello S, De Santis M, Toluoso B, Zoli A, Ferraccioli G. Tumor necrosis factor-alpha inhibitor therapy in erosive polyarthritis secondary to systemic sclerosis. *Ann Intern Med.* 2005;143:918-20.
10. Olivieri I, Gemignani G, Balagi M, et al. Concomitant systemic lupus erythematosus and ankylosing spondylitis. *Ann Rheum Dis* 1990;49: 323e4.
11. Lee JK, Jung SS, Kim TH, Jun JB, Yoo DH, Kim SY. Coexistence of ankylosing spondylitis and mixed connective tissue disease in a single patient. *Clin Exp Rheumatol.* 1999;17:263.
12. Kotevoglou N. Coexistence of ankylosing spondylitis and Behçet's disease. Two cases with atypical presentation and course. *Scand J Rheumatol.* 2003;32:184e5.
13. Ouédraogo DD, Palazzo E, Nlomé-Nzé M, Somogyi- Demerjian N, Meyer O. Ankylosing spondylitis and systemic sclerosis: a rare combination. *Joint Bone Spine.* 2009;76:290-2.
14. Soledade CS, Sampaio-Barros PD, Samara AM, Marques- Neto JF. Unusual association of systemic sclerosis and ankylosing spondylitis. *Clin Rheumatol.* 2005;24:652-4.
15. Kayser C, Alvarenga MC, Neves AS, Gerbase-De Lima M, Andrade LE. Severe ankylosing spondylitis and diffuse systemic sclerosis: case report of a genetic trap. *Scand J Rheumatol.* 2005;34:145-7.